Signalling targets for anticancer drug development
- 31 December 1991
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 12 (5) , 188-194
- https://doi.org/10.1016/0165-6147(91)90545-4
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Suramin blocks intracellular Ca2+ release and growth factor-induced increases in cytoplasmic free Ca2+ concentrationCancer Letters, 1990
- Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitorsJournal of Medicinal Chemistry, 1989
- Mitogenic signalling in murine 3T3 cells: the cyclic AMP pathwayBiochemical Society Transactions, 1989
- Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinasesTrends in Pharmacological Sciences, 1989
- Effect of genistein on topoisomerase activity and on the growth of [VAL 12]Ha-ras-transformed NIH 3T3 cellsBiochemical and Biophysical Research Communications, 1988
- Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinasesBiochemical Pharmacology, 1988
- The molecular heterogeneity of protein kinase C and its implications for cellular regulationNature, 1988
- GROWTH FACTOR RECEPTOR TYROSINE KINASESAnnual Review of Biochemistry, 1988
- Cellular signal transduction and the reversal of malignancyJournal of Cellular Biochemistry, 1987
- Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3.The Journal of Antibiotics, 1986